Please assess the completion status of the following clinical trial:

Trial Title: IV Ibuprofen for Post-Electroconvulsive Therapy Myalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Capable of providing informed consent~* American Society Anesthesiologists (ASA) rating I-III~* Subjects age 18-80 capable of providing consent.~* Subjects undergoing electroconvulsive therapy using succinylcholine as the sole neuromuscular blocking agent.~* Subjects who have scored ≥23 on the Mini-Mental State Examination.~Exclusion Criteria:~* Subjects who have had a recent thrombotic event, myocardial infarction or stroke or episode of Congestive Heart Failure (CHF) within less than 3 months.~* Subjects who have had a recent cardiovascular surgery within the last 3 months.~* Subjects with active Gastrointestinal bleeding~* Subjects who have asthma, itching or allergic type reaction following aspirin or other NSAID administration~* Subjects with a known hypersensitivity to ibuprofen~* Subjects with heart failure, bleeding disorders or kidney failure~* Subjects taking aspirin, Angiotensin converting enzyme (ACE) inhibitors, or anticoagulants within one month.~* Subjects with any devices used to treat pain (intrathecal pumps, spinal cord stimulators etc)~* Subjects with a history of fibromyalgia or chronic myositis~* Subjects who are pregnant~* Subjects who do not have a phone~* Subjects who have had previous ECT~* Subjects receiving toradol (Ketorolac)~* Subjects with reported renal disease within less than 3 months.~* Subjects who have had previous electroconvulsive therapy within the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sugar water (Type: PLACEBO_COMPARATOR): 500 milliliters of intravenous ringers lactate administered over 30 minutes prior to ECT for treatments 1,2 and 3
- Ibuprofen (Type: ACTIVE_COMPARATOR): 300mg/8milliliters of intravenous ibuprofen/caldolor over 30 min in 500mL of ringers lactate to be administered prior to ECT for treatments # 1, 2 and 3

Based on this trial design, predict the completion outcome and termination type (if applicable).